Redeye maintains the valuation of Medicover at SEK 205 per share after the strong report this morning. In 2021 and beyond, we forecast strong recovery for electable procedures in the healthcare services division, growth in diagnostics and fee-for-service pay. We expect Medicover to be able to maintain and even increase dividends over time.